GlassScriptPhysician profile
Sarbani Maitra
NPI 1134360647
$13,490.57
in general payments reported to CMS, 2019-2025
23 companies · $2,764 in 2025
The $2,764 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $147 · 2021: $1,088 · 2022: $3,425 · 2023: $3,691 · 2024: $1,812 · 2025: $2,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,488 · Travel and Lodging: $1,607 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,487.93 |
| Travel and Lodging | $1,607.48 |
| Education | $171.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $3,251.70 | 2021-2025 | Ingrezza |
| Biohaven Pharmaceutical Holding Company LTD. | $2,215.21 | 2022 | |
| Alkermes, INC. | $1,557.01 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $1,323.98 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,320.05 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| E.R. Squibb & Sons, L.L.C. | $802.42 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $649.64 | 2024-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $491.55 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $341.16 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $305.96 | 2024-2025 | Auvelity |
| Lundbeck LLC | $281.16 | 2021-2024 | Abilify Asimtufii, Rexulti |
| Indivior INC. | $273.97 | 2023-2024 | Perseris |
| Janssen Pharmaceuticals, INC | $271.28 | 2022-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $162.46 | 2022 | |
| Bioxcel Therapeutics, INC. | $116.41 | 2023 | Igalmi |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $65.75 | 2022-2023 | Aplenzin |
| Neuronetics, INC. | $45.13 | 2023 | Neurostar Tms Therapy System |
| Takeda Pharmaceuticals U.S.A., INC. | $15.73 | 2023 | Trintellix |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarbani Maitra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.